Innovative Therapeutics VectorY specializes in cutting-edge gene therapy and vectorized antibody platforms, creating opportunities to collaborate with pharmaceutical and biotech companies seeking advanced treatments for neurodegenerative and muscle disorders.

Strategic Partnerships Strong recent collaborations with Shape Therapeutics highlight VectorY’s openness to licensing and partnership opportunities, providing a door for potential co-development and licensing deals with entities interested in neurodegenerative therapies.

Global Expansion The company's expansion into the US market with new offices in Boston indicates a readiness to engage North American partners and investors, opening avenues for business development in a key biotech hub.

Robust Manufacturing With state-of-the-art GMP facilities capable of large-scale AAV vector production, VectorY can support clinical and commercial supply collaborations, making it an attractive manufacturing partner for companies requiring scalable gene therapy production.

Funding & Growth Having secured $138 million in funding and generating revenue between $1 million and $10 million, VectorY presents an appealing opportunity for investors and partners looking to tap into the emerging gene therapy market with a company showing strong growth potential.